|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 799 9th St NW |
Address2 | Suite 210 |
City | WASHINGTON |
State | DC |
Zip Code | 20001 |
Country | USA |
3. Principal place of business (if different than line 2)
City | Irving |
State | TX |
Zip Code | 75062 |
Country | USA |
|
5. Senate ID# 40021-00012
|
||||||||
|
6. House ID# 313240000
|
TYPE OF REPORT | 8. Year | 2023 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Shoshana Krilow |
Date | 10/20/2023 5:45:36 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Medicaid Disproportionate Hospital (DSH) payment cuts - Urged Congress to avoid Medicaid Disproportionate Share Hospital (DSH) payment cuts scheduled to begin in FY 2024. Urged passage of Supporting Safety Net Hospitals Act (H.R. 2665). Supported temporary delay of Medicaid DSH cuts in continuing resolution (H.R. 5860).
Lower Costs, More Transparency Act (H.R. 5378) - Supported inclusion of provision to delay Medicaid DSH payment cuts and provisions similar to those in the Improving Seniors Timely Access to Care Act to update requirements for the use of prior authorization by Medicare Advantage organizations. Opposed adoption of site-neutral payment policies for drug administration and increased fines related to price transparency requirements for hospitals.
Medicare-supported Graduate Medical Education - Supported passage of the Resident Physician Shortage Reduction Act (H.R. 2389/S. 1302).
Medicare Home Infusion - Supported passage of the Preserving Patient Access to Home Infusion Act (S. 1976/H.R. 4104).
Rural health care - Developed and provided feedback to the House Ways and Means Committee RFI related to improving care access in rural and underserved areas. Supported passage of the SAVE Rural Hospitals Act (S. 803/H.R. 3635); the Rural Hospital Closure Relief Act (S. 1571); the Rural Hospital Support Act (S. 1110); the Conrad State 30 and Physician Access Reauthorization Act (H.R. 4924/S. 665). Urged further changes to Rural Emergency Hospital designation.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Shoshana |
Krilow |
|
|
|
Steven |
Rixen |
|
|
|
Jenna |
Stern |
|
|
|
Darren |
Webb |
|
|
|
Alexandria |
Icenhower |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
Hospital Group Purchasing - Advocated to highlight the value that hospital group purchasing organizations provide to hospitals and suppliers. Provided education on how GPOs work in the healthcare supply chain and the role they play in delivering value to healthcare providers.
Drug shortages - Opposed provisions in House Energy and Commerce Committee discussion draft on drug shortages that would exempt sterile injectable products from the 340B Drug Pricing Program, and increase reporting obligations for hospitals as a and group purchasing organizations. Supported elements to increase transparency in prescription drug supply chain and increase reimbursement for generic prescription drugs.
Endorsed passage of the Drug Origin Transparency Act (H.R. 3810).
Endorsed passage of the Biosimilar Red Tape Elimination Act (S. 2305).
Pandemic and All Hazard Preparedness Act (H.R. 4421 and H.R. 4420) - Supported timely passage of legislation to reauthorize the Pandemic and All Hazards Preparedness Act. Advocated for including provisions to increase transparency in the healthcare supply chain and improve hospital and health system emergency preparedness.
340B Drug Pricing Program - Endorsed passage of the Protect 340B Act (H.R. 2534). Opposed legislation (H.R. 3290/S. 1133) that would place cumbersome reporting obligations on 340B covered entities. Continued to urge action to ensure covered entities have access to 340B discounted prices through contract pharmacies. Highlighted critical importance of the 340B program for hospitals.
Social Determinants of Health - Highlighted during congressional briefing how hospitals are investing in social determinants of health to support the health of their community. Highlighted the need for federal agencies to utilize a more comprehensive social needs index like the Vizient Vulnerability Index to identify community health needs and other social drivers of health.
Healthcare Workforce - Urged passage of the Safety from Violence for Healthcare Employees (SAVE) Act (H.R. 2584/S. 2768). Continued to highlight the need to improve healthcare staffing through investments and reauthorization of critical workforce programs, expanding access to unused visas for healthcare workers. Monitored development and introduction of the Bipartisan Primary Care and Health Workforce Act (S.2840).
Children's Hospital Graduate Medical Education (CHGME) - Urged Congress to reauthorize CHGME program (H.R. 3887). Offered support for providing $738 million in funding the CHGME program.
Unique Device Identification (UDI) - Supported improved data standards and validation to improve accuracy of medical device information in the Global Unique Device Identification Database.
Telehealth - Supported passage of the CONNECT for Health Act (S. 2016/H.R. 4189). Continued to advocate for the adoption of permanent telehealth policies to extend flexibilities beyond the current 2024 expiration date.
Medical Device Sterilization - Conducted education and outreach on the potential negative impact on the healthcare supply chain of pending regulations limiting the use of Ethylene Oxide as a medical device sterilant.
Supported passage of the Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR)Act (S. 1355/H.R. 2940).
Supported passage of the Biologics Competition Act (H.R. 1790).
Payer-mandated White Bagging - Urged support for policy updates to place limits on payer-mandated white bagging for medications.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Food & Drug Administration (FDA), Centers For Medicare and Medicaid Services (CMS)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Shoshana |
Krilow |
|
|
|
Steven |
Rixen |
|
|
|
Jenna |
Stern |
|
|
|
Darren |
Webb |
|
|
|
Alexandria |
Icenhower |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAR
16. Specific lobbying issues
Sec. 301 China Tariffs - Continued to advocate for clarity around the expiration of tariff exclusions for products necessary to respond to the COVID-19 pandemic. Supported extending exclusions for key healthcare products.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, U.S. Trade Representative (USTR)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Shoshana |
Krilow |
|
|
|
Steven |
Rixen |
|
|
|
Jenna |
Stern |
|
|
|
Darren |
Webb |
|
|
|
Alexandria |
Icenhower |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAX
16. Specific lobbying issues
Not-for-Profit Hospital Tax-exemption - Provided education and information on hospital tax exemption and what is required to justify and maintain tax-exempt status.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Steven |
Rixen |
|
|
|
Shoshana |
Krilow |
|
|
|
Jenna |
Stern |
|
|
|
Darren |
Webb |
|
|
|
Alexandria |
Icenhower |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address |
|
||||||
City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
Lobbyist Name | Description of Offense(s) |